PVLA
PalvellaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PVLA Profile
Palvella Therapeutics, Inc.
A clinical stage biotechnology company focused on discovering and developing innovative therapies based on Anticalin protein for the treatment of respiratory and cancer diseases
125 Strafford Ave, Suite 360, Wayne, Pennsylvania 19087
--
Palvella Therapeutics, Inc., was incorporated under the laws of Nevada on May 24, 2013. The company is a biotechnology company that has historically discovered and developed Anticalin protein-based drugs that target proven disease pathways in unique and transformative ways. On March 27, 2024, the Company implemented measures to maximize its ability to collect potential milestones from its clinical pipeline of collaborative drug candidates and maintain its ability to consider other strategic options. The company's clinical pipeline includes immuno-oncology or IO bispecific drugs with collaborators, including S095012 (also known as PRS -344) targeting PD-L1 and 4-1BB, SGN-BB228 (also known as PRS -346) targeting CD228 and 4-1BB, and BOS -342 (also known as PRS -342) targeting GPC 3 and 4-1BB. Anticalin protein is proprietary to the company and is a new class of therapies that have been clinically validated through partnerships with leading pharmaceutical companies.
